Filing Flows › Prime Medicine (PRME) › Stock forecast & fair value
Prime Medicine (PRME) stock forecast and price target
Prime Medicine (PRME) trades at $4.65. 11 analysts' median price target is $8.00 (+72%), from $4.25 to $11.00.
Prime Medicine's latest quarter
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PRME stock?
The median of 11 analysts' 12-month targets is $8.00, +72% from $4.65; the range is $4.25 to $11.00. The average rating is strong buy.
Does Prime Medicine usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is PRME stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.